In accordance with this hypothesis, perfusion measurements with MRI and pulsed arterial spin labeling have proven that the A2AR antagonist tozadenant inhibits (i.e., suppresses the overactivity of) the indirect pathway in the brain of Parkinson’s patients [152]. Here, ADORA2A is linked to Parkinsonism.